Imaging multidrug resistance with 4-[18F]fluoropaclitaxel

Area of Science:

• Oncology
• Nuclear Medicine
• Radiochemistry

Background:

• Multidrug resistance (MDR) leads to cancer treatment failure.
• Accurate identification of MDR tumors is crucial for effective therapy selection.
• Current imaging tracers have limitations in specificity and quantification.

Purpose of the Study:

• To evaluate 4-[18F]Fluoropaclitaxel (FPAC) as a PET tracer for identifying MDR tumors.
• To assess the potential of FPAC PET for predicting chemotherapy response.

Main Methods:

• FPAC, a PET-radiolabeled paclitaxel analogue, was studied.
• Biodistribution was assessed in normal volunteers and nonhuman primates.
• FPAC PET imaging was performed in a breast cancer patient.

Main Results:

• FPAC uptake was inversely proportional to MDR expression in preclinical studies.
• Biodistribution in humans was similar to nonhuman primates.
• FPAC localized in a responsive primary tumor but not in partially responsive mediastinal disease.

Conclusions:

• FPAC PET shows promise for noninvasive, pretreatment identification of MDR tumors.
• This imaging approach could facilitate image-guided personalized cancer medicine.